EUVIMEDEUVIMED entdecken
Open Access

Cascade Chatbot: A Scalable Approach to Family-Based Genetic Testing for Hereditary Cancer Syndromes

Lauren B Davis Rivera, Lauren Mitchell iD, Muhammad Danyal Ahsan iD, Isabelle Chandler iD, Emily S Epstein iD, Emerson P Borsato iD, Caitlin Allen iD, Kimberly A Kaphingst iD, Richard L Bradshaw iD, Guilherme Del Fiol iD, Kensaku Kawamoto iD, Anne C Madeo iD und 2 weitere

JCO Clinical Cancer Informatics · 2026

DOI: 10.1200/cci-25-00321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2026. Verfasst von Lauren B Davis Rivera und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY. Hauptthemen laut MEDLINE: Genetic Testing, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AHRQ HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Cascade genetic testing enables identification of relatives at risk of hereditary cancer syndromes, creating opportunities for early detection and prevention. However, uptake of cascade testing remains low, with approximately one-third of eligible relatives completing testing, largely because of reliance on patient-mediated communication. Although clinician-mediated outreach has demonstrated improved efficacy, it is often limited by resource demands. Scalable digital health tools are a promising strategy to address this gap in testing uptake. METHODS In this quality improvement initiative, we developed a digital cascade chatbot to deliver gene-specific education and facilitate access to genetic services among at-risk relatives. Between October 2024 and January 2025, 100 consecutive probands with a hereditary cancer pathogenic variant seen in a gynecologic oncology clinic were offered a cascade chatbot to share with their relatives. The primary outcome was proband acceptance of the cascade chatbot. Secondary outcomes included sharing of the cascade chatbot with at-risk relatives and relatives' subsequent utilization of genetic services. Outcomes were evaluated through telephone follow-up at 2 weeks and 3 months after chatbot introduction. RESULTS Fifty-nine of 100 probands reported having relatives who had not undergone genetic testing. Among this group, 58 (98.3%) accepted the cascade chatbot. At 2-week follow-up, 44 of 58 probands (75.9%) had shared the cascade chatbot with at least one relative, and an additional eight (13.8%) reported plans to share. At 3-month follow-up with probands, 48 (82.8%) probands had shared the cascade chatbot with at least one relative. A total of 122 relatives received the cascade chatbot and 96 (78.7%) were reached for 3-month follow-up. Among the 96 relatives reached, 49 (51.0%) had scheduled or completed a genetics appointment, and of them, 36 (73.5%) had completed testing. CONCLUSION A cascade chatbot was highly acceptable to probands and effectively engaged relatives. Scalable digital health tools may enhance cascade testing and support precision cancer prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingNeoplastic Syndromes, HereditaryHumansFemaleMiddle AgedAdultGenetic Predisposition to DiseaseFamilyMaleGenetic Counseling

Autor:innen und Institutionen

  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY.
  • Genetics and Personalized Cancer Prevention Program, Weill Cornell Medicine, New York, NY.
  • Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT.
  • Department of Public Health Sciences, University of South Carolina, Charleston, SC.
  • Department of Communication and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
  • Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT.

ORCID-Profile: Lauren Mitchell, Muhammad Danyal Ahsan, Isabelle Chandler, Emily S Epstein, Emerson P Borsato, Caitlin Allen, Kimberly A Kaphingst, Richard L Bradshaw, Guilherme Del Fiol, Kensaku Kawamoto, Anne C Madeo, Ravi N Sharaf, Melissa K Frey

Förderung

  • AHRQ HHS
  • NCI NIH HHS

Zitieren

APA

Davis Rivera, L. B., Mitchell, L., Ahsan, M. D., Chandler, I., Epstein, E. S., Borsato, E. P., Allen, C., Kaphingst, K. A., Bradshaw, R. L., Del Fiol, G., Kawamoto, K., Madeo, A. C., Sharaf, R. N., & Frey, M. K. (2026). Cascade Chatbot: A Scalable Approach to Family-Based Genetic Testing for Hereditary Cancer Syndromes. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-25-00321

Vancouver

Davis Rivera LB, Mitchell L, Ahsan MD, Chandler I, Epstein ES, Borsato EP, et al. Cascade Chatbot: A Scalable Approach to Family-Based Genetic Testing for Hereditary Cancer Syndromes. JCO Clinical Cancer Informatics. 2026. doi:10.1200/cci-25-00321

BibTeX
@article{DavisRivera2026,
  author = {Davis Rivera, Lauren B and Mitchell, Lauren and Ahsan, Muhammad Danyal and Chandler, Isabelle and Epstein, Emily S and Borsato, Emerson P and Allen, Caitlin and Kaphingst, Kimberly A and Bradshaw, Richard L and Del Fiol, Guilherme and Kawamoto, Kensaku and Madeo, Anne C and Sharaf, Ravi N and Frey, Melissa K},
  title = {Cascade Chatbot: A Scalable Approach to Family-Based Genetic Testing for Hereditary Cancer Syndromes},
  journal = {JCO Clinical Cancer Informatics},
  year = {2026},
  doi = {10.1200/cci-25-00321}
}
Kostenlos starten →